Table 4 Angiographic and PCI characteristics during initial PCI
Parameter | Total (n = 106) | ACS cohort (n = 68) | Non-ACS cohort (n = 38) | P value |
|---|---|---|---|---|
Lesion type | 0.427 | |||
A | 51 (48.1%) | 29 (42.7%) | 22 (57.9%) | |
B | 28 (26.4%) | 19 (27.9%) | 9 (23.7%) | |
C | 27 (25.5%) | 20 (29.4%) | 7 (18.4%) | |
Calcification | 14 (13.2%) | 7 (10.3%) | 7 (18.4%) | 0.358 |
Disease burden | 0.627 | |||
Single-vessel disease | 55 (51.9%) | 38 (55.9%) | 17 (44.7%) | |
Double-vessel disease | 33 (31.1%) | 18 (26.5%) | 15 (39.5%) | |
Triple-vessel disease | 18 (17.0%) | 12 (17.6%) | 6 (15.8%) | |
Details of PCI | ||||
No. of stents | 1.3 ± 0.6 | 1.3 ± 0.6 | 1.3 ± 0.6 | 0.923 |
Stent length | 27.0 ± 8.7 | 28.2 ± 8.7 | 24.6 ± 8.6 | 0.124 |
Stent diameter | 2.92 ± 0.34 | 2.93 ± 0.36 | 2.90 ± 0.31 | 0.712 |
Pre-dilation | 63 (59.4%) | 43 (63.2%) | 20 (52.6%) | 0.541 |
Post-dilation | 43 (40.5%) | 27 (39.7%) | 16 (42.1%) | 0.944 |
DES type | 0.683 | |||
Paclitaxel | 3 (2.8%) | 3 (4.4%) | – | |
Sirolimus | 70 (66.1%) | 46 (67.6%) | 24 (63.2%) | |
Everolimus | 21 (19.8%) | 12 (17.7%) | 9 (23.7%) | |
Zotarolimus | 12 (11.3%) | 7 (10.3%) | 5 (13.1%) | |
Time to ISR | 26.8 ± 25 | 24.5 ± 24 | 31.9 ± 30.1 | 0.481 |